Use of MarginProbe® in DCIS Patients Presented at San Antonio Breast Cancer Symposium


MarginProbe use reduces re-excision surgeries in patients with diffuse disease

Framingham, MA, December 8, 2011- An analysis of the MarginProbe pivotal study for patients with ductal carcinoma in situ (DCIS) and invasive lobular carcinoma (ILC) were presented today during the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. The results were presented by Dr. Susan K. Boolbol, Chief, Division of Breast Surgery, Beth Israel Medical Center, New York, New York. In patients with DCIS or ILC, adjunctive use of MarginProbe significantly improved surgical outcomes by increasing surgeons’ ability to identify and immediately resect positive margins, reducing the number of patients requiring re-excision by 49% and 64% respectively.

“Ductal carcinoma in situ and ILCrepresent a particular challenge to the breast surgeon,” said Dr. Boolbol. “Current intraoperative techniques are sub-optimal, leading to re-excision rates as high as 40%, as reported in the literature. These study results represent a tremendous opportunity for breast surgeons to improve the quality of care they offer their patients.”

“These results further reinforce the evidence of MarginProbe’s benefit in all disease types, including the most challenging DCIS and lobular cases. These results mirror those seen in Germany in our post-market study,” said Dan Levangie, CEO of Dilon Devices.“Across multiple studies, in the US, Europe, and Israel, adjunctive use of MarginProbe has
consistently led to a 50% reduction in the number of patients requiring re-excision surgery in all disease types.”
About the MarginProbe System

The MarginProbe System enables real time detection of cancer at or near the surface of excised tissue specimens during surgery for breast cancer. The simple and immediate assessment of the surgical margins allows surgeons to immediately excise additional tissue, potentially saving a second procedure. The MarginProbe System is Dune’s first commercial product and is commercially available in Europe. The MarginProbe device is an investigational device in the U.S.
About Dilon Devices

Dilon Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering
surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic
applications. Dilon Devices is a privately held company financed by Apax Partnerssince 2004. It has offices in the U.S., Israel, Germany and Switzerland.[/vc_column_text][/vc_column][/vc_row]

Posted in